Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Wetzel Investment Advisors Inc.

Wetzel Investment Advisors Inc. cut its position in Moderna, Inc. (NASDAQ:MRNA) by 8.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,190 shares of the company’s stock after selling 302 shares during the period. Wetzel Investment Advisors Inc.’s holdings in Moderna were worth $213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in MRNA. Vanguard Group Inc. boosted its stake in shares of Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after acquiring an additional 5,129,800 shares during the last quarter. International Assets Investment Management LLC boosted its stake in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after acquiring an additional 316,552 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of Moderna by 1,212.9% in the first quarter. Intech Investment Management LLC now owns 330,805 shares of the company’s stock worth $35,251,000 after acquiring an additional 305,609 shares during the last quarter. Matrix Capital Management Company LP boosted its stake in shares of Moderna by 60.8% in the first quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock worth $77,789,000 after acquiring an additional 276,000 shares during the last quarter. Finally, Motley Fool Wealth Management LLC acquired a new stake in shares of Moderna in the first quarter worth approximately $21,317,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently commented on MRNA. TD Cowen reduced their price objective on Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a research report on Friday, September 13th. Oppenheimer downgraded Moderna from an “outperform” rating to a “market perform” rating in a research report on Friday, September 13th. Barclays reduced their price objective on Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research report on Monday, September 16th. The Goldman Sachs Group reduced their price objective on Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Finally, Sanford C. Bernstein initiated coverage on Moderna in a research report on Thursday, October 17th. They set a “market perform” rating and a $55.00 price objective on the stock. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $94.65.

Insider Buying and Selling

In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 1,321 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 3,184 shares of company stock valued at $238,531 in the last three months. 15.70% of the stock is owned by corporate insiders.

Moderna Trading Up 0.4 %

Shares of NASDAQ MRNA opened at $54.87 on Monday. Moderna, Inc. has a twelve month low of $52.26 and a twelve month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $64.61 and a 200-day simple moving average of $100.99. The stock has a market capitalization of $21.09 billion, a PE ratio of -3.55 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same period in the previous year, the firm posted ($3.62) earnings per share. The company’s revenue was down 29.9% on a year-over-year basis. On average, equities analysts forecast that Moderna, Inc. will post -9.88 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.